New hope for teens with stubborn hives: xolair study shows promise
NCT ID NCT06053801
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study looked at whether Xolair (omalizumab) is safe and effective for Chinese teenagers with chronic spontaneous urticaria (long-lasting hives and itching) that don't get better with standard antihistamines. Fifty-five teens took part, receiving Xolair for 12 weeks and then were followed for 4 more weeks. The main goals were to track side effects and see how much the itching improved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Fuzhou, Fujian, 350025, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510091, China
-
Novartis Investigative Site
Changsha, Hunan, 410008, China
-
Novartis Investigative Site
Nantong, Jiangsu, 226000, China
-
Novartis Investigative Site
Dalian, Liaoning, 116000, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310001, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310006, China
-
Novartis Investigative Site
Wenzhou, Zhejiang, 325000, China
-
Novartis Investigative Site
Beijing, 100069, China
-
Novartis Investigative Site
Shanghai, 200443, China
Conditions
Explore the condition pages connected to this study.